J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal
By Bhanvi Satija and Puyaan Singh (Reuters) -Johnson & Johnson said on Monday it will buy neurological drugmaker Intra-Cellular Therapies for $14.6 billion, its biggest deal in at least two years, ...
J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...
News Medical13d
Preclinical MRI of neurological diseases from morphological imaging to tissue property mapping
An example of chemical shift imaging of the mouse brain acquired via BioSpec Maxwell ... and neurotransmitter concentrations in neurological disorders. Built upon metabolic signatures, CEST ...
J&J to acquire drugmaker Intra-Cellular Therapies for $14.6 billion
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...
Johnson & Johnson To Buy Drugmaker Intra-Cellular For $14.6 Billion
Johnson & Johnson (JNJ) has announced that it plans to acquire drugmaker Intra-Cellular Therapies (ITCI), which specializes in neurological treatments, for $14.6 billion U.S. Johnson & Johnson will ...